Sporadic adenoma or ulcerative colitis associated neoplasia? The endoscopist's information has an impact on diagnosis and patient management.

[1]  Caitlyn A. Miller,et al.  Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation. , 2018, Inflammatory bowel diseases.

[2]  Marc J. Williams,et al.  Evolutionary history of human colitis-associated colorectal cancer , 2018, Gut.

[3]  P. Meltzer,et al.  Dynamics of Genome Alterations in Crohn's Disease–Associated Colorectal Carcinogenesis , 2018, Clinical Cancer Research.

[4]  Martin L. Miller,et al.  Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease–Associated Colorectal Cancers , 2018, Clinical Cancer Research.

[5]  B. George,et al.  Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis. , 2017, Gastrointestinal endoscopy.

[6]  Zachary J. Heins,et al.  Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. , 2016, Gastroenterology.

[7]  A. Hart,et al.  Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview , 2015, The American Journal of Gastroenterology.

[8]  Alan Barkun,et al.  SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. , 2015, Gastrointestinal endoscopy.

[9]  W. Selby,et al.  Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  A. Amiot,et al.  European evidence based consensus for endoscopy in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[11]  E. Horváth-Puhó,et al.  Cancer Risk in Inflammatory Bowel Disease According to Patient Phenotype and Treatment: A Danish Population-Based Cohort Study , 2013, The American Journal of Gastroenterology.

[12]  G. Petris,et al.  European consensus on the histopathology of inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[13]  R. Feakins,et al.  Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines , 2013, Journal of Clinical Pathology.

[14]  Laurent Beaugerie,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. , 2013, Journal of Crohn's & colitis.

[15]  E. Kuipers,et al.  Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus , 2012, Gut.

[16]  Douglas K Rex,et al.  Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. , 2012, Gastroenterology.

[17]  L. Peyrin-Biroulet,et al.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  R. McLeod,et al.  Position Statement on the Diagnosis and Management of olorectal Neoplasia in Inflammatory Bowel Disease , 2022 .

[19]  P. Kosmidis,et al.  Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. , 2009, Anticancer research.

[20]  T. Dassopoulos,et al.  Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. , 2009, Gastrointestinal endoscopy.

[21]  S. Parsons,et al.  Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry , 2009, Histopathology.

[22]  J. Askling,et al.  Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. , 2009, Gastroenterology.

[23]  D. Hommes,et al.  More right‐sided IBD‐associated colorectal cancer in patients with primary sclerosing cholangitis , 2008, Inflammatory bowel diseases.

[24]  M. Duffy,et al.  Surveillance of patients at increased risk of colon cancer: inflammatory bowel disease and other conditions. , 2008, Gastroenterology clinics of North America.

[25]  N. Harpaz,et al.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.

[26]  A. Forbes,et al.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. , 2006, Gastroenterology.

[27]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[28]  A. Forbes,et al.  Most dysplasia in ulcerative colitis is visible at colonoscopy. , 2004, Gastrointestinal endoscopy.

[29]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[30]  Noam Harpaz,et al.  Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. , 2003, Gastroenterology.

[31]  M. Vieth,et al.  Die schwierige Differenzialdiagnose der sporadischen Adenome und kolitisassoziierten intraepithelialen Neoplasien bei Colitis ulcerosa , 2003, Der Pathologe.

[32]  P. Heidenreich,et al.  Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. , 2002, Gastrointestinal endoscopy.

[33]  C. Rubio,et al.  Low-Grade Dysplasia in Extensive, Long-Standing Inflammatory Bowel Disease , 2002, Diseases of the colon and rectum.

[34]  J. Goldblum,et al.  Interobserver Variability in the Diagnosis of Ulcerative Colitis-Associated Dysplasia by Telepathology , 2002, Modern Pathology.

[35]  C. Fenoglio-Preiser,et al.  A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene , 2001, Histopathology.

[36]  K Abrams,et al.  Inter‐observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis , 2001, The Journal of pathology.

[37]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[38]  K. Hatakeyama,et al.  Mutations of p53 in Morphologically Non‐neoplastic Mucosa of Long‐standing Ulcerative Colitis , 2001, Japanese journal of cancer research : Gann.

[39]  J. Goldblum,et al.  The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression , 2000, American Journal of Gastroenterology.

[40]  R. Machinami,et al.  p53 immunohistochemistry of ulcerative colitis‐associated with dysplasia and carcinoma , 1999, Pathology international.

[41]  M. Vieth,et al.  The differentiation of true adenomas from colitis-associated dysplasia in ulcerative colitis: a comparative immunohistochemical study. , 1999, Human pathology.

[42]  J. Goldblum,et al.  Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis , 1999, American Journal of Gastroenterology.

[43]  N. Harpaz,et al.  Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. , 1995, Cancer research.

[44]  N. Williams,et al.  Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis , 1993, The British journal of surgery.

[45]  M. Stolte,et al.  Clinical and pathomorphological findings in patients with colorectal carcinoma complicating ulcerative colitis. , 1993, Zeitschrift fur Gastroenterologie.

[46]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[47]  J. Jass,et al.  Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. , 1989, Human pathology.

[48]  A. Price,et al.  Observer variation in the assessment of dysplasia in ulcerative colitis , 1988, Histopathology.

[49]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[50]  A. Ananthakrishnan,et al.  ACG Clinical Guideline: Ulcerative Colitis in Adults. , 2019, The American journal of gastroenterology.

[51]  [Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) - AWMF Registry 021/009]. , 2018, Zeitschrift fur Gastroenterologie.

[52]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[53]  J. Jass,et al.  Tumours of the colon and rectum: Hyperplastic polyposis , 2000 .

[54]  D. Wentura,et al.  Wissenschaftliche Beobachtung: eine Einführung , 1997 .